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Recent work of several laboratories has identified 
FACT (facilitates chromatin transcription) protein 
complex as an emerging target for development of 
anticancer drugs and suggested a mechanism of FACT 
action during transcription and cell differentiation. 
FACT is the transcription and replication factor 
[1], which can stimulate transcript elongation through 
chromatin in vitro [2, 3]. Human FACT is a heterodimer 
composed of two subunits Spt16 and SSRP1 and has a 
histone chaperone activity [3, 4]. In vivo, FACT and RNA 
polymerase II (Pol II) co-localize and display similar 
kinetics of recruitment and chromosome tracking [5, 6]. 
FACT also maintains the nucleosome integrity during 
transcription initiation and transcript elongation by Pol II 
[6-9]. Currently, two different models have been proposed 
to explain the functions of FACT to nucleosomes. On one 
hand, it has been suggested that FACT-assisted histone 
H2A/H2B dimer dissociation from nucleosome facilitates 
transcription through chromatin [3] and perhaps chromatin 
re-assembly. On the other hand, the studies of yeast FACT 
suggested that it can globally affect the nucleosome 
structure to allow access of regulatory proteins to histone-
covered DNA [10, 11]. 
In a recent careful biochemical study from laboratory 
of K. Luger [12] interactions between FACT and its 
various potential interaction targets in chromatin (histones 
H2A-H2B and H3-H4, histone tails, nucleosomal and 
linker DNA) were quantified. It was shown that FACT 
preferentially binds to H2A-H2B dimer and this high-
affinity binding is largely mediated by the acidic C-terminal 
domain of the Spt16 subunit. The observation that FACT 
competes with DNA for a shared interaction interface 
on H2A-H2B dimer suggests a possible mechanism of 
FACT-facilitated DNA displacement from the histone 
octamer and possibly subsequent nucleosome recovery. 
Indeed, as various processive DNA-targeted enzymes (e.g. 
polymerases and ATP-dependent chromatin remodelers) 
encounter nucleosomes and attempt to displace histones 
from DNA, progression of the enzymes should be greatly 
facilitated by the FACT-dimer interactions. The recovery 
of chromatin structure could be facilitated by chaperone 
activity of FACT though facilitated re-binding of the 
dimers to chromatin or their more efficient survival during 
transcription, as was suggested recently [13].
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Figure 1: FACT as a regulatory hub in cell differentiation and carcinogenesis. As RNA polymerase II (Pol II) encounters 
nucleosomes (1) and uncoils nucleosomal DNA from core histones (2), FACT interacts with the H2A/H2B dimer and facilitates transcription 
through chromatin. Binding of FACT results in cell growth inhibition through inhibition of NK-κB and activation of p53 by CK2 
phosphorylation. Curaxins intercalate into the DNA, induce a conformational change in the DNA and interfere with recruitment of FACT.Oncotarget 2011; 2:  830 - 832 831 www.impactjournals.com/oncotarget
using  immunohistochemical methods and NCBI Gene 
Expression Omnibus data analysis (laboratory of K. 
Gurova) have shown that the SSRP1 and SPT16 subunits 
are expressed in a coordinated manner, and the levels of 
expression are highly variable within the tissues [14]. 
The levels of expression are higher in non-differentiated 
and cancer cells, and do not correlate with expression 
of  the Ki67 proliferation marker, suggesting that that 
FACT expression is more related to differentiation than 
to proliferation. Induction of oncogenes in different 
cells in most cases results in an increased expression of 
FACT subunits. Furthermore, tumor cells are sensitive to 
FACT downregulation, suggesting that FACT could be 
an important new target for development of anti-cancer 
drugs.
The latter line of research has been extended in 
another work from Gurova group [15]. It was shown that 
cancer cells, like undifferentiated cells, contain higher 
levels of FACT. Small DNA-intercalating molecules, 
curaxins, have a strong anticancer activity, activate p53 and 
inhibit NF-kB without causing detectable genotoxicity. 
The effects of curaxins on p53 and NF-kB, as well as their 
toxicity to cancer cells, result from “chromatin trapping” 
of FACT (depletion of soluble, functionally active FACT), 
presumably through interaction with DNA-bound curaxins 
that is particularly detrimental for cancer cells. Trapping 
of FACT leads to phosphorylation of the p53 by casein 
kinase 2 (CK2) and inhibition of NF-kB-dependent genes 
that require FACT activity during transcript elongation 
stage. 
How can the changes in FACT content during cell 
differentiation and carcinogenesis be rationalized in the 
framework of the current models of FACT action? Since 
FACT works primarily during transcript elongation 
step (likely via interactions with H2A/H2B dimers, Fig. 
1), it is required in large amounts in cells where gene 
expression occurs at a higher level, such as cancer or 
undifferentiated cells. Therefore these cells are more 
sensitive to inhibitors affecting expression or activity of 
FACT. Indeed, recent proteomic studies of Xiong et al. 
[16] suggest that proteins involved in DNA replication, 
chromatin remodeling, and Pol II-dependent transcription 
are down-regulated in differentiated cells. Future analysis 
of the molecular mechanisms of FACT action and its 
interaction with anticancer drugs should reveal whether 
FACT expression plays a regulatory role in differentiation 
and carcinogenesis, and should result in development of 
more efficient cancer therapies.
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